secwatch.observer — SEC 8-K summary
======================================

Issuer:     Century Therapeutics, Inc. (IPSC)
CIK:        0001850119
Form:       8-K
Filed at:   2024-07-08T23:59:59+00:00
Accession:  0001104659-24-078322
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Century Therapeutics updates pipeline; CNTY-101 achieves 40% CRR at higher doses; SLE trial starts Q3 2024
--------------------------------------------------------------------------------

- CNTY-101 ELiPSE-1 Phase 1 data: 30% CRR, 40% ORR overall; 40% CRR, 60% ORR at highest dose levels in Schedule A.
- CNTY-101 shows favorable safety: no GvHD, low-grade CRS/ICANS, manageable outpatient administration.
- Phase 1 CALiPSO-1 trial for SLE (systemic lupus erythematosus) initiated early Q3 2024; initial data expected by YE 2024.
- Cash of $249.9M at 1Q24 end provides runway into 2026.
- Pursuing additional autoimmune regulatory submissions for CNTY-101 in 2H 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1850119/000110465924078322/0001104659-24-078322-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1850119/000110465924078322/tm2418927d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-078322

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer